Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Kidney damage is a major complication of current antirejection medicines used in
transplantation. An increasing number of brittle diabetics are successfully receiving a
pancreas transplant. One of the challenges following pancreas transplant is that a patient
can develop kidney damage from one of their antirejection medicines, tacrolimus. The
objective of this study is to substitute a new antirejection medicine which does not cause
kidney damage, belatacept for tacrolimus in patients that have developed signs of tacrolimus
related kidney damage to slow the progression of kidney disease.